BioPharma Resources

Drug Trial Radar · NCT03254966

Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients

Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Safety and Efficacy of SHR0302 in Patients With Moderate to Severe Active Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Sep 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 194 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

194

Actual

Start

Nov 24, 2017

Primary completion

Apr 16, 2019

Study completion Oct 12, 2019

Sponsor

Sponsor type
Industry
First posted
Aug 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of SHR0302 tablets (SHR0302) in subjects with moderate to severe active rheumatoid arthritis.

Conditions

  • Rheumatoid Arthritis

Interventions

  • SHR0302Drug

    Oral tablets

  • PlaceboDrug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects achieving an American College of Rheumatology (ACR)20 response at Week 12Time frame: Baseline - Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.